Evidence map›Paper›PMID 27831904›Full record

ArticleScience translational medicine2016

Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.

Florian Scherer, David M Kurtz, Aaron M Newman, Henning Stehr, Alexander F M Craig, Mohammad Shahrokh Esfahani, Alexander F Lovejoy, Jacob J Chabon, Daniel M Klass, Chih Long Liu and 12 more

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04237168 (Non-invasive Tumor Immunoglobulin Gene Next Generation Sequencing), which is not on this map. Cited by 271 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
271citing papers in PubMed, 3 pooled it
17.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04237168 unknown statusnot on this mapstarted 2020, after this paper: background citation

Non-invasive Tumor Immunoglobulin Gene Next Generation Sequencing (IgNGS) in Diffuse Large B Cell Lymphoma (DLBCL): Prognostic Implications and Assessment of Tumor Response

TypeobservationalSponsorFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauRan2020 to 2022Enrolled30ConditionsLymphoma, Large B-Cell, DiffuseArmsIgNGS from circulating tumor DNA
3 · Its place in the literature

Who cites it

271 citing papers in PubMed, 3 syntheses or guidelines pooled it, 474 citations in OpenAlex.

  1. Pooled it
  2. A genetic profiling guideline to support diagnosis and clinical management of lymphomas.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Guideline
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

211 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 1 country.

Florian SchererDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
David M KurtzDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Aaron M NewmanDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Henning StehrStanford Cancer Institute, Stanford University, Stanford, CA 94305, USA.
Alexander F M CraigDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Mohammad Shahrokh EsfahaniDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Alexander F LovejoyInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA 94305, USA.
Jacob J ChabonInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA 94305, USA.
Daniel M KlassDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Chih Long LiuDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Li ZhouStanford Cancer Institute, Stanford University, Stanford, CA 94305, USA.
Cynthia GloverDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Brendan C VisserDivision of Surgical Oncology, Department of Surgery, Stanford University, Stanford, CA 94305, USA.
George A PoultsidesDivision of Surgical Oncology, Department of Surgery, Stanford University, Stanford, CA 94305, USA.
Ranjana H AdvaniDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Lauren S MaedaDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Neel K GuptaDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Ronald LevyDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Robert S OhgamiDepartment of Pathology, Stanford University, Stanford, CA 94305, USA.
Christian A KunderDepartment of Pathology, Stanford University, Stanford, CA 94305, USA.
Maximilian DiehnInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA 94305, USA. arasha@stanford.edu diehn@stanford.edu.
Ash A AlizadehDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA. arasha@stanford.edu diehn@stanford.edu.
Stanford University · USCalifornia Institute for Regenerative Medicine · US

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Melinda L. Telli · 2007 to 2026
$71.4M
Modeling the Molecular Determinants of Induced Anti-Tumor Immune Responses in Mantle Cell LymphomaU01CA194389 · NCI · STANFORD UNIVERSITY · PI ALIZADEH, ASH ARASH, DAVIS, MARK MORRIS · 2015 to 2019
$3.1M
Developing a genomic approach for cancer screeningDP2CA186569 · NCI · STANFORD UNIVERSITY · PI DIEHN, MAXIMILIAN · 2013 to 2013
$2.4M
Cancer Systems Biology Scholars ProgramR25CA180993 · NCI · STANFORD UNIVERSITY · PI PLEVRITIS, SYLVIA KATINA · 2014 to 2018
$2.2M
Postdoctoral Training in the Radiation ScincesT32CA121940 · NCI · STANFORD UNIVERSITY · PI GRAVES, EDWARD E. · 2007 to 2018
$2.1M
Noninvasive monitoring of lung cancer patients treated with radiotherapyR01CA188298 · NCI · STANFORD UNIVERSITY · PI ALIZADEH, ASH ARASH, DIEHN, MAXIMILIAN · 2015 to 2019
$1.8M
Ultrasensitive Quantitation of Circulating Tumor DNAK99CA187192 · NCI · STANFORD UNIVERSITY · PI NEWMAN, AARON M · 2015 to 2016
$342k
Damon Runyon Cancer Research Foundation CI-71-14NCI NIH HHS DP2 CA186569NCI NIH HHS K99 CA187192NCI NIH HHS P30 CA124435NCI NIH HHS R01 CA188298NCI NIH HHS R25 CA180993NCI NIH HHS T32 CA121940NCI NIH HHS U01 CA194389
6 · The paper itself

Abstract

Patients with diffuse large B cell lymphoma (DLBCL) exhibit marked diversity in tumor behavior and outcomes, yet the identification of poor-risk groups remains challenging. In addition, the biology underlying these differences is incompletely understood. We hypothesized that characterization of mutational heterogeneity and genomic evolution using circulating tumor DNA (ctDNA) profiling could reveal molecular determinants of adverse outcomes. To address this hypothesis, we applied cancer personalized profiling by deep sequencing (CAPP-Seq) analysis to tumor biopsies and cell-free DNA samples from 92 lymphoma patients and 24 healthy subjects. At diagnosis, the amount of ctDNA was found to strongly correlate with clinical indices and was independently predictive of patient outcomes. We demonstrate that ctDNA genotyping can classify transcriptionally defined tumor subtypes, including DLBCL cell of origin, directly from plasma. By simultaneously tracking multiple somatic mutations in ctDNA, our approach outperformed immunoglobulin sequencing and radiographic imaging for the detection of minimal residual disease and facilitated noninvasive identification of emergent resistance mutations to targeted therapies. In addition, we identified distinct patterns of clonal evolution distinguishing indolent follicular lymphomas from those that transformed into DLBCL, allowing for potential noninvasive prediction of histological transformation. Collectively, our results demonstrate that ctDNA analysis reveals biological factors that underlie lymphoma clinical outcomes and could facilitate individualized therapy.

Indexed as

AdultAgedAged, 80 and overAlgorithmsBiomarkers, TumorBiopsyCell-Free SystemCirculating Tumor DNAFemaleGenotypeHumansImmunoglobulinsLymphoma, B-CellLymphoma, Large B-Cell, DiffuseMaleMiddle AgedBiomarkers, TumorCirculating Tumor DNAImmunoglobulins

Identifiers

PMID27831904
PMCPMC5490494
OpenAlexW2551589138

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.